• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Lupin, Concord, receive US FDA approval for Mycophenolate Mofetil tablets USP

expresspharmaAugust 07, 2020

Tag: lupin , FDA , Mycophenolate Mofetil tablets , Concord Biotech

Lupin, in alliance with Concord Biotech, announced that it has received approval from the United States Food and Drug Administration (US FDA) for Mycophenolate Mofetil tablets USP, 500 mg, to market a generic version of CellCept tablets of Roche Palo Alto (Roche).

Mycophenolate Mofetil Tablets are indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate Mofetil tablets USP, 500 mg had an annual sales of approximately $96 million in the US (IQVIA MAT Mar 2020).


Previous:Lupin signs exclusive distribution deal with ForDoz Pharma for complex injectable assets

Next:Hainan Shuangcheng Pharmaceuticals Co., Ltd.- Exhibitor Webinar

Related News

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Lupin, Concord, receive US FDA approval for Mycophenolate Mofetil tablets USP | Pharmasources.com

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may like
More>>

Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Lupeol-8%-Lupinus Albus Extracts

Lupeol-8%-Lupinus Albus Extracts
Mycophenolate Mofetil Tablets

Mycophenolate Mofetil Tablets
Sirolimus (FDA)

Sirolimus (FDA)
9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)

9,9-Bis(4-amino-3-fluorophenyl) Fluorene (FFDA)
Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Dobutamine HCL (FDA)

Dobutamine HCL (FDA)
Clindamycin Phosphate( FDA)

Clindamycin Phosphate( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service